Physician profile
Shahdeen Alam
NPI 1851898399
$5,468.42
in general payments reported to CMS, 2019-2025
39 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $414 · 2022: $1,123 · 2023: $1,328 · 2024: $1,503 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,932.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,931.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $704.50 | 2022-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $626.14 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $506.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $454.45 | 2021-2024 | Repatha, Otezla |
| Abbott Laboratories | $393.00 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $318.43 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $271.11 | 2022-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $243.62 | 2022-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $237.27 | 2022-2024 | |
| Pfizer INC. | $221.36 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.98 | 2022-2025 | Xifaxan |
| Inari Medical, INC. | $127.28 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Dexcom, INC. | $107.33 | 2022-2024 | Dexcom G6 Transmitter |
| Jazz Pharmaceuticals INC. | $96.28 | 2025 | |
| Lilly USA, LLC | $94.28 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $79.50 | 2023 | Sunosi |
| Silk Road Medical, INC. | $72.31 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Alexion Pharmaceuticals, INC. | $64.30 | 2022-2023 | Ultomiris |
| Exact Sciences Corporation | $63.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gilead Sciences, INC. | $54.01 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $52.91 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $50.51 | 2022-2023 | |
| Astellas Pharma US INC | $46.00 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $45.17 | 2023-2024 | Quviviq |
| Xeris Pharmaceuticals, INC. | $41.61 | 2023 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $41.03 | 2024 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.86 | 2024 | Lifevest |
| Harmony Biosciences LLC | $33.96 | 2024 | |
| Vanda Pharmaceuticals INC. | $31.66 | 2025 | Fanapt |
| Corium, LLC | $31.43 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $23.51 | 2022 | |
| Merck Sharp & Dohme LLC | $22.75 | 2021 | |
| Dynavax Technologies Corporation | $21.14 | 2023 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.41 | 2025 | Jardiance |
| Boston Scientific Corporation | $17.16 | 2025 | General - Pain Management |
| Medtronic, INC. | $16.55 | 2021 | |
| Currax Pharmaceuticals LLC | $14.13 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 2022 | |
| Opko Pharmaceuticals, LLC | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahdeen Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.